长期COVID中的肾脏结局
采用逆概率加权生存回归分析,发现COVID-19幸存者急性期后AKI、eGFR下降、ESKD及MAKE风险均显著升高,且风险随急性期病情严重程度递增。
要点
- COVID-19幸存者急性期后AKI风险增加(aHR 1.94)。
- ESKD风险增加近3倍(aHR 2.96),需重视长期随访。
- eGFR年下降幅度随急性期病情严重程度递增。
核心结论
- COVID-19幸存者急性期后肾脏结局风险增加,应关注肾脏疾病。
主要发现
- COVID-19幸存者急性期后AKI风险aHR 1.94(95%CI 1.86-2.04)。
- eGFR下降≥30%、≥40%、≥50%的aHR分别为1.25(95%CI 1.14-1.37)、1.44(95%CI 1.37-1.51)、1.62(95%CI 1.51-1.74)。
- ESKD风险aHR 2.96(95%CI 2.49-3.51),MAKE风险aHR 1.66(95%CI 1.58-1.74)。
- 与非感染对照相比,COVID-19幸存者eGFR年下降额外幅度分别为:未住院者-3.26(95%CI -3.58至-2.94)、住院者-5.20(95%CI -6.24至-4.16)、ICU入住者-7.69(95%CI -8.27至-7.12)ml/min/1.73m2。
临床怎么用
- 对COVID-19幸存者进行急性期后随访时应关注肾脏疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 is associated with increased risk of post-acute sequelae involving pulmonary and extrapulmonary organ systems-referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. METHODS: We built a cohort of 1,726,683 US Veterans identified from March 1, 2020 to March 15, 2021, including 89,216 patients who were 30-day survivors of COVID-19 and 1,637,467 non-infected controls. We examined risks of AKI, eGFR decline, ESKD, and major adverse kidney events (MAKE). MAKE was defined as eGFR decline ≥50%, ESKD, or all-cause mortality. We used inverse probability-weighted survival regression, adjusting for predefined demographic and health characteristics, and algorithmically selected high-dimensional covariates, including diagnoses, medications, and laboratory tests. Linear mixed models characterized intra-individual eGFR trajectory. RESULTS: Beyond the acute illness, 30-day survivors of COVID-19 exhibited a higher risk of AKI (aHR, 1.94; 95% CI, 1.86 to 2.04), eGFR decline ≥30% (aHR, 1.25; 95% CI, 1.14 to 1.37), eGFR decline ≥40% (aHR, 1.44; 95% CI, 1.37 to 1.51), eGFR decline ≥50% (aHR, 1.62; 95% CI, 1.51 to 1.74), ESKD (aHR, 2.96; 95% CI, 2.49 to 3.51), and MAKE (aHR, 1.66; 95% CI, 1.58 to 1.74). Increase in risks of post-acute kidney outcomes was graded according to the severity of the acute infection (whether patients were non-hospitalized, hospitalized, or admitted to intensive care). Compared with non-infected controls, 30-day survivors of COVID-19 exhibited excess eGFR decline (95% CI) of -3.26 (-3.58 to -2.94), -5.20 (-6.24 to -4.16), and -7.69 (-8.27 to -7.12) ml/min per 1.73 m2 per year, respectively, in non-hospitalized, hospitalized, and those admitted to intensive care during the acute phase of COVID-19 infection. CONCLUSIONS: Patients who survived COVID-19 exhibited increased risk of kidney outcomes in the post-acute phase of the disease. Post-acute COVID-19 care should include attention to kidney disease.
引用
- Bowe B, Xie Y, Xu E, et al. Kidney Outcomes in Long COVID. J Am Soc Nephrol. 2021. PMID: 34470828. doi:10.1681/ASN.2021060734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。